BUFFALO, N.Y., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company
dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, today announced
recent product launches from Athenex Pharmaceutical Division (‘APD”). These launches highlight Athenex’s growing commercial
portfolio and strong relationships with FDA approved partners worldwide.
Athenex has brought the following products to market in its Specialty (finished-dose specialty injectable products) and 503B
(outsourced sterile preparations) businesses:
Specialty Products
- Oxaliplatin 5mg/mL, 10 mL; 5 mg/mL, 20 mL; (2 SKUs; vials)
- Vancomycin 500 mg; 1 g; (2 SKUs; vials)
- Polymyxin B 500,000 units; (1 SKU; vial)
- Ketorolac 15 mg/mL 1 mL; 30 mg/mL 1 mL; 30 mg/mL 2 mL (3 SKUs; vials)
- Midazolam 2mg/2 mL; 25 mg/5 mL; 50 mg/10 mL; (3 SKUs; vials)
- Terbutaline Sulfate Injection 1mg/1 mL; (1 SKU; vial)
- Tranexamic Acid 100 mg/ml 10 mL (1 SKU; vial)
503B Products
- Epinephrine in 250 mL Dextrose bags (2 SKUs)
- Norepinephrine in 250 mL Dextrose bags (3 SKUs)
- Phenylephrine in 250 mL Saline bags (5 SKUs)
Jeffrey Yordon, Athenex’s Chief Operating Officer and President of APD, stated, “We are proud to bring so many products to the
U.S. market in our first year as a commercial entity. These launches underscore the capabilities of our Commercial business, as
well as the strength of our partner relationships. We remain focused on expanding our pharmaceuticals business and expect to see
additional product launches from our commercial business by year-end. The infrastructure and capabilities we are building through
our specialty pharmaceutical business not only allow Athenex to rapidly expand our product portfolio, but also provide us with a
strong commercial platform and broad-ranging expertise to leverage across our proprietary platform.”
Athenex’s products emphasize quality and enhance patient safety. cGMP processes are followed for each of Athenex’s products, and
a Certificate of Analysis is provided for each batch of 503B products so customers are able to see measurable results from
repeatable tests. Additionally, Athenex’s AccuraSEE, a proprietary and highly differentiated approach to package and labeling, has
a unique design to give caregivers accurate information and reduce the risk of medication errors.
About Athenex, Inc.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the
discovery and development of next generation drugs for the treatment of cancer. Athenex is organized around three platforms
including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. Athenex’s Oncology Innovation
Platform generates clinical candidates through an extensive understanding of kinases, including novel binding sites, human
absorption biology and through the application of Athenex’s proprietary research and selection processes in the lab. The Company’s
current clinical pipeline is derived from two different platform technologies Athenex calls Orascovery and Src Kinase Inhibition.
The Orascovery platform is based on the novel oral P-glycoprotein pump inhibitor molecule HM30181A, through which Athenex is able
to facilitate oral absorption of traditional cytotoxics, which Athenex believes may offer improved patient tolerability and
efficacy as compared to IV administration of the same cytotoxics. The Src Kinase Inhibition platform refers to novel small molecule
compounds that have multiple mechanisms of action, including the inhibition of the activity of Src Kinase and the inhibition of
tubulin polymerization during cell division. Athenex believes the combination of these mechanisms of action provides a broader
range of anti-cancer activity as compared to either mechanism of action alone. Athenex’s employees worldwide are dedicated to
improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and
Clarence, New York, Cranford, New Jersey, Houston, Texas, Chicago, Illinois, Hong Kong, Taipei Taiwan, and multiple locations in
Chongqing, China.
CONTACT: Nick Riehle Tel: +1-716-427-2952 Athenex, Inc.
